In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Input: Consider Input: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Right to Try Act''.

SEC. 2. USE OF UNAPPROVED MEDICAL PRODUCTS BY PATIENTS DIAGNOSED WITH A 
              TERMINAL ILLNESS.

    (a) In General.--Notwithstanding the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 301 et seq.), the Controlled Substances Act (21 
U.S.C. 801 et seq.), and any other provision of Federal law, the 
Federal Government shall not take any action to prohibit or restrict--
            (1) the production, manufacture, distribution, prescribing, 
        or dispensing of an experimental drug, biological product, or 
        device that--
                    (A) is intended to treat a patient who has been 
                diagnosed with a terminal illness; and
                    (B) is authorized by, and in accordance with, State 
                law; and
            (2) the possession or use of an experimental drug, 
        biological product, or device--
                    (A) that is described in subparagraphs (A) and (B) 
                of paragraph (1); and
                    (B) for which the patient has received a 
                certification from the patient's treating physician in 
                accordance with subsection (b).
    (b) Physician Certification.--A certification by the patient's 
treating physician referred to in subsection (a)(2)(B) must include 
each of the following:
            (1) A certification that the physician--
                    (A) is in good standing with the physician's 
                certifying organization or board; and
                    (B) has personally examined the patient.
            (2) A certification that there is no reason to conclude the 
        experimental drug, biological product, or device poses an 
        unreasonable and significant risk of danger to the patient.
            (3) A certification that the patient has been diagnosed 
        with a terminal disease or condition and does not have any 
        treatment options that--
                    (A) are comparable to treatment using the 
                experimental drug, biological product, or device or 
                otherwise satisfactory; and
                    (B) are approved, licensed, or cleared for 
                commercial distribution under section 505, 510(k), or 
                515 of the Federal Food, Drug, and Cosmetic Act (21 
                U.S.C. 355, 360(k), 360(e)) or section 351 of the 
                Public Health Service Act (42 U.S.C. 262) and are 
                available to diagnose, monitor, or treat the patient's 
                disease or condition.
            (4) A certification that the probable risk to the patient 
        from the experimental drug, biological product, or device is 
        not greater than the probable risk from the patient's disease 
        or condition.
            (5) A certification that the physician has provided the 
        patient with a written statement and oral explanation of the 
        medical treatment to be provided using the experimental drug, 
        biological product, or device.
            (6) An acknowledgement signed by the patient (or the 
        patient's legal representative) that the physician has provided 
        the written statement and oral explanation required by 
        paragraph (5), and has disclosed the following:
                    (A) That the medical treatment using the 
                experimental drug, biological product, or device is 
                experimental or nonconventional.
                    (B) That the experimental drug, biological product, 
                or device has not been approved, licensed, or cleared 
                for commercial distribution under section 505, 510(k), 
                or 515 of the Federal Food, Drug, and Cosmetic Act (21 
                U.S.C. 355, 360(k), 360(e)) or section 351 of the 
                Public Health Service Act (42 U.S.C. 262) for any 
                indication.
                    (C) The material risks generally recognized by a 
                reasonably prudent physician of the medical treatment's 
                side effects.
                    (D) An explanation of the medical treatment, 
                including the expected frequency and duration of the 
                treatment.
    (c) No Liability or Use of Outcomes.--
            (1) No liability.--Notwithstanding any other provision of 
        law, no liability shall lie against a producer, manufacturer, 
        distributor, prescriber, dispenser, possessor, or user of an 
        experimental drug, biological product, or device for the 
        production, manufacture, distribution, prescribing, dispensing, 
        possession, or use of an experimental drug, biological product, 
        or device that is in compliance, with subsection (a).
            (2) No use of outcomes.--Notwithstanding any other 
        provision of law, the outcome of any production, manufacture, 
        distribution, prescribing, dispensing, possession, or use of an 
        experimental drug, biological product, or device that was done 
        in compliance with subsection (a) shall not be used by a 
        Federal agency reviewing the experimental drug, biological 
        product, or device to delay or otherwise adversely impact 
        review or approval of such experimental drug, biological 
        product, or device.
    (d) Rules of Construction.--Nothing in this Act shall be construed 
to--
            (1) require a manufacturer or other person to make 
        available any experimental drug, biological product, or device; 
        or
            (2) prohibit a manufacturer or other person from receiving 
        compensation or recovering costs for the production, 
        manufacture, distribution, or sale of an experiment drug, 
        biological product, or device.
    (e) Definitions.--In this section:
            (1) Biological product.--The term ``biological product'' 
        has the meaning given to such term in section 351 of the Public 
        Health Service Act (42 U.S.C. 262).
            (2) Device; drug.--The terms ``device'' and ``drug'' have 
        the meanings given to such terms in section 201 of the Federal 
        Food, Drug, and Cosmetic Act (21 U.S.C. 321).
            (3) Experimental drug, biological product, or device.--The 
        term ``experimental drug, biological product, or device'' means 
        a drug, biological product, or device that--
                    (A) has successfully completed a phase 1 clinical 
                investigation;
                    (B) remains under investigation in a clinical trial 
                approved by the Food and Drug Administration; and
                    (C) is not approved, licensed, or cleared for 
                commercial distribution under section 505, 510(k), or 
                515 of the Federal Food, Drug, and Cosmetic Act (21 
                U.S.C. 355, 360(k), 360(e)) or section 351 of the 
                Public Health Service Act (42 U.S.C. 262).
            (4) Phase 1 clinical investigation.--The term ``phase 1 
        clinical investigation'' means a phase 1 clinical 
        investigation, as described in section 312.21 of title 21, Code 
        of Federal Regulations (or any successor regulations).
            (5) Terminal illness.--The term ``terminal illness'' has 
        the meaning given to such term in the State law specified in 
        subsection (a)(1)(B).

Output: Right to Try Act This bill requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that are authorized by state law and intended to treat terminally ill patients. Patients receiving these treatments must be certified by a physician as having exhausted all other treatment options and as being at greater risk from their medical condition than the treatment. The physician must explain the treatment to the patient, including that the treatment is experimental, and the patient, or the patient's legal representative, must acknowledge the explanation. A manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment. The outcome of manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment. The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration (FDA); and (3) not be approved, licensed, or cleared for sale by the FDA.  


Input: Consider Input: SECTION 1. PUBLIC HEALTH SERVICE ACT; LIABILITY PROTECTIONS FOR HEALTH-
              CENTER PRACTITIONERS PROVIDING SERVICES IN EMERGENCY 
              AREAS.

    (a) In General.--Section 224(g) of the Public Health Service Act 
(42 U.S.C. 233(g)) is amended--
            (1) in paragraph (1)(B)(ii), by striking ``subparagraph 
        (C)'' and inserting ``subparagraph (C) and paragraph (6)''; and
            (2) by adding at the end the following paragraph:
    ``(6)(A) Subject to subparagraph (C), paragraph (1)(B)(ii) applies 
to health services provided to individuals who are not patients of the 
entity involved if, as determined under criteria issued by the 
Secretary, the following conditions are met:
            ``(i) The services are provided by a contractor or employee 
        of the entity who is a physician or other licensed or certified 
        health care practitioner and who is otherwise deemed to be an 
        employee for purposes of paragraph (1)(A) when providing 
        services with respect to the entity.
            ``(ii) The services are provided in an emergency area (as 
        defined in subparagraph (D)).
            ``(iii) The services of the contractor or employee 
        (referred to in this paragraph as the `out-of-area 
        practitioner') are provided under an arrangement with--
                    ``(I) an entity that is deemed to be an employee 
                for purposes of paragraph (1)(A) and that serves the 
                emergency area involved (referred to in this paragraph 
                as an `emergency-area entity)'; or
                    ``(II) a Federal agency that has responsibilities 
                regarding the provision of health services in such area 
                during the emergency.
            ``(iv) The purposes of the arrangement are--
                    ``(I) to coordinate, to the extent practicable, the 
                provision of health services in the emergency area by 
                the out-of-area practitioner with the provision of 
                services by the emergency-area entity, or by the 
                Federal agency, as the case may be;
                    ``(II) to identify a location in the emergency area 
                to which such practitioner should report for purposes 
                of providing health services, and to identify an 
                individual or individuals in the area to whom the 
                practitioner should report for such purposes; and
                    ``(III) to verify the identity of the practitioner 
                and that the practitioner is licensed or certified by 
                one or more of the States.
            ``(v) With respect to the licensure or certification of 
        health care practitioners, the provision of services by the 
        out-of-area practitioner in the emergency area is not a 
        violation of the law of the State in which the area is located.
    ``(B) In issuing criteria under subparagraph (A), the Secretary 
shall take into account the need to rapidly enter into arrangements 
under such subparagraph in order to provide health services in 
emergency areas promptly after the emergency begins.
    ``(C) Subparagraph (A) applies with respect to an act or omission 
of an out-of-area practitioner only to the extent that the practitioner 
is not immune from liability for such act or omission under the 
Volunteer Protection Act of 1997.
    ``(D) For purposes of this paragraph, the term `emergency area' 
means a geographic area for which--
            ``(i) the Secretary has made a determination under section 
        319 that a public health emergency exists; or
            ``(ii) a presidential declaration of major disaster has 
        been issued under section 401 of the Robert T. Stafford 
        Disaster Relief and Emergency Assistance Act.''.
    (b) Effective Date.--With respect to paragraph (6) of section 
224(g) of the Public Health Service Act, as added by subsection (a) of 
this section:
            (1) Except as provided in this subsection, an arrangement 
        under subparagraph (A)(iii) of such paragraph (6) is deemed to 
        be in effect for any health professional who, within the 
        meaning of such paragraph--
                    (A) is an employee or contractor of a health center 
                under section 330 of such Act; and
                    (B) served or is serving as an out-of-area 
                practitioner in any emergency area declared as a result 
                of Hurricane Katrina or Hurricane Rita.
            (2) Such paragraph (6) is deemed to have taken effect on 
        August 27, 2005, for purposes of paragraph (1) of this 
        subsection. Such paragraph (6) otherwise takes effect on the 
        date of the enactment of this Act.
            (3) Paragraph (1) of this subsection applies until the 
        expiration of the 48-hour period beginning on the date on which 
        the Secretary of Health and Human Services publishes in the 
        Federal Register a notice that the applicability of such 
        paragraph is being terminated.

Output: Amends the Public Health Service Act to deem certain physicians or other licensed or certified health care practitioners to be employees of the Public Health Service for purposes of any civil action that may arise due to services provided in an emergency area by a contractor or an employee of a qualified health center. Provides that such services must be provided under an arrangement with a qualified health center or with a federal agency with responsibility for providing health services in the emergency area.


Input: Consider Input: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``United States-Cuba Trademark 
Protection Act of 2003''.

SEC. 2. FINDINGS AND PURPOSE.

    (a) Findings.--Congress makes the following findings:
            (1) Trademarks and trade names are vital assets of the many 
        United States companies that engage in international trade.
            (2) Worldwide sales of branded products of United States 
        companies contribute in important ways to the livelihood of 
        American workers and the well-being and continued healthy 
        growth of numerous United States businesses. These sales 
        depend, in turn, on the security of the United States 
        trademarks and trade names protected by reciprocal treaties and 
        agreements for the protection of intellectual property.
            (3) Among such treaties and agreements are the Agreement on 
        Trade-Related Aspects of Intellectual Property Rights (TRIPS) 
        of the World Trade Organization, the Inter-American Convention 
        for Trademark and Commercial Protection, and the Madrid 
        Protocol.
            (4) The United States should ensure that the trademark and 
        trade names of United States companies continue to be protected 
        abroad by working to ensure that countries comply with 
        intellectual property rights treaties and agreements. At the 
        same time, the United States should adhere to its obligations 
        under such treaties and agreements.
            (5) Hundreds of United States companies have registered 
        their trademarks in Cuba in order to ensure the exclusive right 
        to use those trademarks when the United States trade embargo on 
        that country is lifted. Indeed, following the enactment of the 
        Trade Sanctions Reform and Export Enhancement Act of 2000, many 
        United States companies are already exporting branded food 
        products to Cuba.
            (6) The United States District Court for the Southern 
        District of New York ruled that section 211 of the Department 
        of Commerce and Related Agencies Appropriations Act, 1999 
        abrogates, with respect to Cuba, the Inter-American Convention 
        on Trademarks and Commercial Protection, and the court's ruling 
        was affirmed by the United States Court of Appeals for the 
        Second Circuit.
            (7) Cuba's international remedy under customary 
        international law, as codified by Article 60 of the 1969 Vienna 
        Convention on Treaties, for a breach by the United States of 
        the Inter-American Convention, is to suspend or revoke the 
        protections Cuba currently affords United States trademarks and 
        trade names.
            (8) In order to preserve the rights of United States 
        nationals holding trademarks in Cuba, the United States must 
        repeal section 211 of the Department of Commerce and Related 
        Agencies Appropriations Act, 1999, and should take the 
        necessary steps to promote the long-term protection of 
        trademarks, trade names, and domain names held by United States 
        nationals in that country.
            (9) The recent actions by the Government of Cuba to 
        prosecute and imprison unfairly critics of the government are 
        unacceptable and should be met with strong condemnation.
            (10) Promoting greater respect for the rule of law in Cuba, 
        including through the provisions of this Act, will it is hoped 
        diminish the likelihood for actions taken in the future that 
        undermine operation of the rule of law or disregard fundamental 
        fairness in administrative and juridical proceedings.
    (b) Purpose.--The purpose of this Act is to promote global 
intellectual property rights protections by ensuring that the United 
States and the Republic of Cuba continue to comply with their 
obligations under international trademark agreements and 
understandings.

SEC. 3. ADHERENCE TO INTERNATIONAL AGREEMENTS AND UNDERSTANDINGS.

    (a) Consultations With Cuba.--The President shall direct the 
Secretary of State to initiate consultations with the Republic of Cuba 
not later than December 31, 2003, in order to obtain assurances that 
the Republic of Cuba will--
            (1) continue to adhere to--
                    (A) the Paris Convention for the Protection of 
                Industrial Property;
                    (B) the Inter-American Convention for Trademark and 
                Commercial Protection; and
                    (C) the Madrid Agreement Concerning the 
                International Registration of Marks and Protocol 
                Relating to the Madrid Agreement Concerning the 
                International Registration of Marks;
            (2) implement the Joint Recommendation Concerning 
        Provisions on the Protection of Well-Known Marks adopted by the 
        General Assembly of the World Intellectual Property 
        Organization (Pub 833 E) in September 1999; and
            (3) commit that the manager of the Country-Code Top-Level 
        Domain (ccTLD) will subscribe to the Uniform Dispute Resolution 
        Procedure (UDRP) approved by the Internet Corporation for 
        Assigned Names and Numbers (ICANN) and provide to United States 
nationals nondiscriminatory access to such procedures.
    (b) Consultation With Secretary of Commerce.--The Secretary of 
State shall initiate and conduct the consultations under subsection (a) 
in consultation with the Secretary of Commerce.
    (c) Reports to Congress.--The Secretary of State and the Secretary 
of Commerce shall submit to the Congress a report on the progress and 
results of the consultations under subsection (a) not later than 6 
months after the date of the enactment of this Act and not later than 
every 6 months thereafter.
    (d) Repeal of Prohibition on Transactions or Payments With Respect 
to Certain United States Intellectual Property.--
            (1) Repeal.--Section 211 of the Department of Commerce and 
        Related Agencies Appropriations Act, 1999 (as contained in 
        section 101(b) of division A of Public Law 105-277; 112 Stat. 
        2681-88) is repealed.
            (2) Regulations.--The Secretary of the Treasury shall issue 
        such regulations as are necessary to carry out the repeal made 
        by paragraph (1), including removing any prohibition on 
        transactions or payments to which subsection (a)(1) of section 
        211 of the Department of Commerce and Related Agencies 
        Appropriations Act, 1999 applied.

SEC. 4. REGISTRY OF U.S. TRADEMARKS AND WELL-KNOWN MARKS IN CUBA.

    (a) Registry of U.S. Trademarks.--Not later than December 31, 2003, 
the Director of the Patent and Trademark Office shall establish a 
registry of trademarks each of which is owned by a United States 
national and was registered in, or submitted for registration to, the 
Republic of Cuba on or after January 1, 1959.
    (b)  Registry of well-known marks.--
            (1) Establishment.--Not later than December 31, 2003, the 
        Director of the Patent and Trademark Office shall establish a 
        registry of trademarks each of which is owned by a United 
        States national and met the requirements for a well-known mark 
        in the Republic of Cuba under Article 6bis of the Paris 
        Convention for the Protection of Industrial Property as of 
        December 31, 1958, and the Joint Recommendation Concerning 
        Provisions on the Protection of Well-Known Marks adopted by the 
        General Assembly of the World Intellectual Property Association 
        (Pub 833 E) in September 1999.
            (2) Requirements for inclusion on registry.--The Director 
        of the Patent and Trademark Office shall require any applicant 
        seeking to register a well-known mark on the registry 
        established under paragraph (1) to supply documentation to 
        establish that the mark met the requirements set forth in 
        paragraph (1).
    (c) Accessibility.--The Director of the Patent and Trademark Office 
shall ensure that each registry established under subsections (a) and 
(b)--
            (1) is accessible to the public through the Internet;
            (2) allows trademark examiners and applicants seeking to 
        register trademarks on the registry to send and receive 
        communications electronically;
            (3) allows the United States Patent and Trademark Office to 
        process, maintain, and search electronically the contents and 
        history of each application to register a trademark, and 
        trademark registration, included in the registry; and
            (4) allows the public to access and search electronically 
        the contents and history of each such application and trademark 
        registration.

SEC. 5. AMENDMENTS TO CUBAN ASSET CONTROL REGULATIONS.

    The Secretary of the Treasury shall amend the Cuban Assets Control 
Regulations (part 515 of title 31, Code of Federal Regulations) so 
that--
            (1) the following transactions by any person who is not a 
        designated national are authorized:
                    (A) the filing and renewal of a blocked foreign 
                domain name, the transfer or receipt of a blocked 
                foreign domain name, and the filing and prosecution of 
                proceedings to determine rights to a blocked foreign 
                domain name and the prosecution of defenses to such 
                proceedings; and
                    (B) the filing and renewal of a blocked foreign 
                trade name, the transfer or receipt of a blocked 
                foreign trade name, and the filing and prosecution of 
                proceedings related to a blocked foreign trade name and 
                the prosecution of defenses to such proceedings;
            (2)(A) the transfer or receipt of any trademark, trade 
        name, or domain name subject to United States law in which a 
        designated national has an interest is authorized; and
            (B) the filing and prosecution of opposition and 
        infringement proceedings related to any trademark or trade name 
        in which a designated national has an interest, the filing and 
        prosecution of proceedings to determine rights to any domain 
        name in which a designated national has an interest, and the 
        prosecution of defenses to such proceedings, are authorized; 
        and
            (3) the payment of fees to the government of any foreign 
        country, either directly or through an attorney or 
        representative, is authorized for research of registries, 
        directories, and government records with respect to blocked 
        foreign trademarks, blocked foreign trade names, or blocked 
        foreign domain names, and the protection and enforcement 
        thereof.

SEC. 6. CONFORMING AMENDMENTS.

    (a) International Conventions.--Section 44 of the Trademark Act of 
1946 (15 U.S.C. 1126) is amended by adding at the end the following:
    ``(j)(1) Any designated national shall be entitled to the benefits 
of this Act to the extent necessary to give effect to any provision of 
any convention or treaty relating to trade or commercial names, or 
relating to the repression of unfair competition, to which the United 
States and the Republic of Cuba are parties, or to any reciprocal 
rights relating to trade or commercial names or the repression of 
unfair competition, that are extended by the Republic of Cuba to 
nationals of the United States by law. The absence of commercial 
activities within the United States shall not constitute a lack of 
standing or any other reason for the dismissal of any action brought by 
any such designated national pursuant to this subsection.
    ``(2) No other provision of this section shall be construed to 
limit the applicability of paragraph (1).
    ``(3) As used in this subsection, the term `designated national' 
has the meaning given that term in subpart C of part 515 of title 31, 
Code of Federal Regulations, as in effect on April 28, 2003, and 
includes any national of a foreign country that is a successor-in-
interest to that designated national.''.
    (b) Civil Actions.--Section 43(a) of the Trademark Act of 1946 (15 
U.S.C. 1125(a)) is amended by adding at the end the following:
    ``(4)(A) For purposes of this subsection, any person who is engaged 
in the bona fide production, distribution, marketing, or sale of 
spirits outside the United States and who lawfully uses a mark or 
geographical indication in connection with such spirits shall be 
considered to be or likely to be damaged by a mark or geographical 
indication--
            ``(i) which, when used on or in connection with other 
        spirits, identifies a place other than origin of such other 
        spirits; and
            ``(ii) of which the first use in commerce on or in 
        connection with such other spirits was made on or after one 
        year after the date on which the WTO Agreement (as defined in 
        section 2(9) of the Uruguay Round Agreements Act) entered into 
        force with respect to the United States.
The preceding sentence shall also apply to any person in any proceeding 
under section 13 or 14 of this Act.
    ``(B) As used in this paragraph, the term `spirits' means any 
article provided for in heading 2207 or 2208 of the Harmonized Tariff 
Schedule of the United States.''.

SEC. 7. AUTHORITY OF COURTS.

    United States courts shall have the authority to recognize, 
enforce, or otherwise validate any assertion by a designated national 
of rights in any mark or trade name based on common law rights or 
registration or under subsection (b) or (e) of section 44 of the 
Trademark Act of 1946. In this subsection, the term ``designated 
national'' includes any national of a foreign country that is a 
successor-in-interest to that designated national.

SEC. 8. DEFINITIONS.

    In this Act:
            (1) Blocked foreign domain name.--The term ``blocked 
        foreign domain name'' means a domain name in which a designated 
        national has an interest, including any domain name issued by a 
        designated national.
            (2) Blocked foreign trade name.--The term ``blocked foreign 
        trade name'' means any trade name in which a designated 
        national has an interest, including any such trade name issued 
        by a designated national.
            (3) Blocked foreign trademark.--The term ``blocked foreign 
        trademark'' has the meaning given that term in section 
        515.528(c) of title 31, Code of Federal Regulations, as in 
        effect on April 28, 2003.
            (4) Designated national.--The term ``designated national'' 
        has the meaning given that term in subpart C of part 515 of 
        title 31, Code of Federal Regulations, as in effect on April 
        28, 2003.
            (5) Director of the patent and trademark office.--The term 
        ``Director of the Patent and Trademark Office'' means the Under 
        Secretary of Commerce for Intellectual Property and Director of 
        the United States Patent and Trademark Office.
            (6) Domain name; mark; trademark.--The terms ``domain 
        name'', ``mark'', and ``trademark'' have the meanings given 
        those terms in section 45 of the Trademark Act of 1946.
            (7) Interest.--The term ``interest'' has the meaning given 
        that term in section 515.312 of title 31, Code of Federal 
        Regulations, as in effect on April 28, 2003.
            (8) Trademark act of 1946.--The term ``Trademark Act of 
        1946'' means the Act entitled ``An Act to provide for the 
        registration and protection of trademarks used in commerce, to 
        carry out the provisions of certain international conventions, 
        and for other purposes'', approved July 5, 1946 (15 U.S.C. 1051 
        et seq.).
            (9) Trade name.--The term ``trade name'' means a trade name 
        or commercial name as those terms are defined in section 45 of 
        the Trademark Act of 1946.
            (10) United states national.--The term ``United States 
        national'' means--
                    (A) any United States citizen; or
                    (B) any other legal entity which is organized under 
                the laws of the United States, or of any State, the 
                District of Columbia, or any commonwealth, territory, 
                or possession of the United States, and which has its 
                principal place of business in the United States.


Output: United States-Cuba Trademark Protection Act of 2003 - Requires the President to direct the Secretary of State to obtain assurances that the Republic of Cuba will: (1) adhere to specified international agreements for the protection of intellectual property; (2) implement the Joint Recommendation Concerning Provisions on the Protection of Well-Known Marks; and (3) subscribe to dispute resolution procedures approved by the Internet Corporation for Assigned Names and Numbers.

Repeals provisions of the Department of Commerce and Related Agencies Appropriations Act, 1999 prohibiting certain transactions, payments, or U.S. court recognition with respect to confiscated marks, trade names, or commercial names.

Requires the Director of the Patent and Trademark Office to establish an electronic and publicly accessible registry of U.S. trademarks and well-known marks in Cuba.

Amends the Cuban Assets Control Regulations to authorize: (1) specified transactions and proceedings regarding blocked foreign domain and trade names by any person who is not a designated national; (2) the transfer or receipt of any trademark, trade name, or domain name subject to U.S. law in which a designated national has an interest, as well as related proceedings; and (3) the payment of fees to foreign governments for research with respect to blocked foreign trademarks, trade names, and domain names, and related enforcement.

Makes conforming amendments to the Trademark Act of 1946.

Gives U.S. courts authority to validate any assertion by a designated national of rights in any mark or trade name based on common law rights or registration under specified provisions of the Trademark Act.